Haemonetics Co. (NYSE:HAE) Receives $101.22 Consensus Price Target from Brokerages

Shares of Haemonetics Co. (NYSE:HAE) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $101.22.

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Needham & Company LLC reduced their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, Barrington Research cut their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th.

Haemonetics Stock Performance

Shares of HAE opened at $64.09 on Monday. The firm has a market capitalization of $3.22 billion, a P/E ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics has a 52 week low of $58.80 and a 52 week high of $97.97. The stock has a 50 day moving average price of $65.42 and a two-hundred day moving average price of $74.47. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HAE. TD Waterhouse Canada Inc. bought a new stake in Haemonetics in the 4th quarter valued at about $25,000. Covestor Ltd increased its stake in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics in the fourth quarter worth about $62,000. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the period. Finally, AlphaQuest LLC lifted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.